Orlistat
- Generic Name
- Orlistat
- Brand Names
- Alli, Xenical, Alli (previously Orlistat GSK)
- Drug Type
- Small Molecule
- Chemical Formula
- C29H53NO5
- CAS Number
- 96829-58-2
- Unique Ingredient Identifier
- 95M8R751W8
- Background
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.
...
- Indication
Orlistat is indicated for obesity management including weight loss and weight maintenance when used in combination with calorie reduction in overweight and obese adults; this indication applies to both the prescription formulation of 120 mg and the over-the-counter formulation of 60 mg. Orlistat in the 120 mg prescription formulation is also indicated to red...
- Associated Conditions
- Weight Gain
- Associated Therapies
- Weight Reduction
Anti-obesity Effects of Dandelion (Taraxacum Officinale L.)
- Conditions
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- October 6 University
- Target Recruit Count
- 120
- Registration Number
- NCT06625736
- Locations
- 🇪🇬
October 6 University Hospital, Giza, Egypt
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Affiliated Hospital of Nantong University
- Target Recruit Count
- 102
- Registration Number
- NCT06501326
- Locations
- 🇨🇳
Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT05816343
- Locations
- 🇺🇸
UT southwestern Medical Center, Dallas, Texas, United States
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 500
- Registration Number
- NCT05579249
- Locations
- 🇺🇸
Nutrition Research Centre, Loma Linda, California, United States
Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Shanghai 10th People's Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT05496075
- Locations
- 🇨🇳
Shanghai Tenth People's hospital, Shanghai, Shanghai, China
EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 74
- Registration Number
- NCT04531176
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Weight Loss Aid in an Exposed Population
- Conditions
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Emory University
- Target Recruit Count
- 100
- Registration Number
- NCT03582722
- Locations
- 🇺🇸
Michele Marcus, Atlanta, Georgia, United States
Research of Intensive Metabolic Intervention Before Pregnancy in PCOS
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT03383068
- Locations
- 🇨🇳
Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, China
Orlistat for the Treatment of Type I Hyperlipoproteinemia
- Conditions
- Interventions
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT02767531
- Locations
- 🇺🇸
UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas, United States
Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02706067
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.